Jasper Therapeutics, Inc.
JSPR
$0.73
$0.033.98%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -20.75% | 14.33% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -15.93% | -28.63% | |||
| Operating Income | 15.93% | 28.63% | |||
| Income Before Tax | -135.09% | 87.10% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -135.09% | 87.10% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -135.09% | 87.10% | |||
| EBIT | 15.93% | 28.63% | |||
| EBITDA | 15.96% | 27.40% | |||
| EPS Basic | -135.21% | 87.12% | |||
| Normalized Basic EPS | -134.77% | 86.36% | |||
| EPS Diluted | -135.21% | 87.12% | |||
| Normalized Diluted EPS | -134.77% | 86.36% | |||
| Average Basic Shares Outstanding | 0.09% | 0.03% | |||
| Average Diluted Shares Outstanding | 0.09% | 0.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||